Ocular Therapeutix (OCUL) Bounces From The Bottom; EU OKs Vodafone Group (VOD), Liberty Global (LBTYA, LBTYB, LBTYK) Dutch Merger


Shares of Ocular Therapeutix, Inc. (Nasdaq:OCUL) touched a new 52-week low of $4.04 in intraday trading Wednesday, finally closing at $4.20, up $0.03 (or +0.72%)

The company’s stock soared more than 20% in the extended session after it reported plans for a resubmission to its New Drug Application (NDA) for DEXTENZA soon, aiming to get FDA approval to bring to market its dexamethasone insert for the treatment of post-surgical ocular pain as rapidly as possible

Ocular Therapeutix, which is focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, has 24.77M Shares Outstanding, Market Capitalization (intraday) of $104.77M and OCUL stock one-year range is now from $4.04 to $23.99 per share



The European Commission gave green light – subject to conditions – to the proposed creation of a joint venture in the Netherlands by Vodafone Group Plc (Nasdaq:VOD) and cable company Liberty Global plc (Nasdaq:LBTYA) (Nasdaq:LBTYB) (Nasdaq:LBTYK)

VOD stock surged $0.41 (or +1.33%) to $31.19, with a total volume of 6,179,707 shares traded on Wednesday

Vodafone Group, which provides services to mobile voice, messaging, data and fixed line, has 26.56B Shares Outstanding, Market Capitalization (intraday) of $82.91B and VOD stock 52-week range is between $27.92 and $38.43 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/